In the high-stakes arena of organ transplantation, the viability of donor organs is often compromised by the very processes meant to preserve them. Ischemia, cold storage, and reperfusion inflict significant cellular damage, particularly to mitochondria, the powerhouses of the cell. A new review, published in Hepatobiliary & Pancreatic Diseases International, explores a groundbreaking strategy: transplanting healthy mitochondria into donor organs during machine perfusion to actively repair damage rather than merely slow its progression.
This approach addresses a critical limitation in current preservation methods. Traditional static cold storage slows metabolic activity but fails to restore the mitochondrial function essential for energy production, cellular survival, and inflammatory regulation. Machine perfusion offers a window of opportunity for intervention, yet most existing systems focus on maintaining organ function rather than rebuilding it. By delivering viable mitochondria during this ex vivo period, researchers hope to recondition organs that might otherwise be discarded.
The review synthesizes evidence from preclinical models across multiple organs. In pig hearts, autologous skeletal-muscle mitochondria delivered via coronary circulation during normothermic perfusion improved contractile recovery, reduced oxygen consumption, and, in one study, decreased infarct size by over 75%. Human platelet-derived mitochondria successfully entered rat cardiomyocytes, supporting ATP production and cell viability while reducing reactive oxygen species. In lungs, mitochondrial supplementation during ex vivo lung perfusion improved oxygenation, reduced pulmonary vascular resistance, and dampened inflammatory markers, even when mitochondria originated from a different individual or species without triggering acute immune rejection. Porcine kidneys also showed enhanced metabolic activity and mitochondrial biogenesis when treated with autologous mitochondria.
The proposed mechanism involves mitochondrial uptake through endocytosis or membrane fusion, replacing damaged organelles and restoring oxidative phosphorylation and redox balance. While evidence for liver transplantation remains limited to non-transplant injury models, the consistency of benefits across organs is encouraging.
Lead author Dr. [Name], from Wake Forest University, emphasizes the paradigm shift: "We should not view donor organs as tissues that can only be protected from further decline. Mitochondria could give transplant teams a practical way to address energy failure while the organ is already connected to a perfusion system." The key now is establishing shared standards for mitochondrial quality, source, dose, and delivery methods.
If validated clinically, this therapy could rescue marginal organs, extend safe preservation times, and facilitate long-distance organ sharing. It could also integrate seamlessly into existing machine-perfusion platforms, combining treatment and viability testing in one workflow. However, significant hurdles remain, including standardizing isolation methods, determining the optimal mitochondrial source (autologous, allogeneic, or xenogeneic), and clarifying long-term immune effects. Rigorous large-animal studies and carefully designed human trials are essential to translate these promising preclinical findings into clinical practice.
